Siemens Healthineers AG
0PMJ.L
London Stock Exchange33.66
EUR
-0.44
- -
Siemens Healthineers AG
0PMJ.L
(London Stock Exchange)
Recent
price
33.66
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Siemens Healthineers AG develops, manufactures, and sells a comprehensive portfolio of medical technology products and services, including medical imaging systems such as magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound; laboratory and point-of-care diagnostics encompassing immunochemistry, hematology, coagulation, urinalysis, blood gas analysis, and molecular tests; advanced therapies featuring angiography systems, mobile C-arms, and robotic-assisted platforms for minimally invasive interventions; and oncology solutions through its Varian segment providing integrated radiation oncology equipment, digital solutions, and multi-modality cancer care technologies. The company operates four primary business segments—Imaging, Diagnostics, Varian, and Advanced Therapies—serving healthcare providers worldwide with a focus on disease prevention, detection, diagnosis, and treatment across oncology, cardiology, neurology, and other clinical fields; it maintains a global presence in over 70 countries with local operations supporting more than 72,000 employees. Founded in 2017 as a spin-off from Siemens AG, which remains its majority shareholder, Siemens Healthineers AG is headquartered in Forchheim, Germany. In November 2025, the company announced a new strategic phase called "Elevating Health Globally," restructuring its financial reporting into three segments—Imaging for prevention and detection, a combined Precision Therapy segment integrating Varian, Advanced Therapies, and Ultrasound for treatment, and Diagnostics—while targeting 5-7% annual group revenue growth and double-digit adjusted earnings per share growth through 2030, with an emphasis on AI-enabled solutions for stroke, cancer, cardiovascular, and neurodegenerative diseases. Recent developments include the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis in late 2024, enhancing its radioligand imaging manufacturing and distribution capabilities in Europe; expansion of Value Partnerships with over 200 major customers for recurring revenues; and sustained double-digit growth in emerging markets. Parent company Siemens AG further reduced its stake by selling approximately a 2% interest in February 2025, raising €1.45 billion to support corporate purposes including the Altair Engineering acquisition, amid considerations of a potential spin-off.